Craddock Jessica, Markovic-Plese Silva
Department of Neurology, University of North Carolina at Chapel Hill, 105 Mason Farm Road, Chapel Hill, NC 27599, USA.
Expert Rev Clin Pharmacol. 2015 May;8(3):283-96. doi: 10.1586/17512433.2015.1036030.
Relapsing-remitting multiple sclerosis (RRMS), a CNS inflammatory demyelinating disease, is one of the most prevalent causes of chronic disability in young adults. Studies of the disease pathogenesis have identified multiple therapeutic targets. The number of approved disease modifying therapies has almost doubled within the past 5 years, which creates a challenge for medical professionals to stay abreast of their use in everyday practice. This manuscript provides an overview of available injectable, oral, and intravenous therapies for RRMS, and offers guidance in selecting an appropriate therapy. Focus is on the recently approved and emerging monoclonal antibody therapies, because they offer more selective and superior therapeutic efficacy compared with injectable and oral disease modifying therapies. We discuss the outlook for monoclonal antibodies and their role in RRMS treatment in the future.
复发缓解型多发性硬化症（RRMS）是一种中枢神经系统炎性脱髓鞘疾病，是年轻成年人慢性残疾的最常见原因之一。对该疾病发病机制的研究已确定了多个治疗靶点。在过去5年中，获批的疾病修饰疗法数量几乎翻了一番，这给医学专业人员在日常实践中紧跟其使用情况带来了挑战。本文概述了RRMS可用的注射、口服和静脉治疗方法，并为选择合适的治疗方法提供指导。重点是最近获批和新出现的单克隆抗体疗法，因为与注射和口服疾病修饰疗法相比，它们具有更具选择性和更优越的治疗效果。我们讨论了单克隆抗体的前景及其在未来RRMS治疗中的作用。
